Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

Sugahara, Kunio; Maeda, Yasuhiro; Shimano, Kyoko; Mogami, Akira; Kataoka, Hirotoshi; Ogawa, Kei; Hikida, Kumiko; Kumagai, Hiroshi; Asayama, Mahoko; Yamamoto, Toshinobu; Harada, Tomohiko; Ni, Pingping; Inoue, Shinsuke; Kawaguchi, Atsuhiro

doi:10.1111/bph.13641

Public

Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

Published in British Journal of Pharmacology • Oct 13, 2016

Authors:

Kunio Sugahara

Yasuhiro Maeda

Kyoko Shimano

Abstract

Background and Purpose We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT‐1303), a second‐generation sphingosine 1‐phosphate (S1P) receptor modulator, designed to reduce the bradycardia associated with fingolimod and other S1...

Subject

Fingolimod

Sphingosine-1-phosphate receptor

Agonist

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!